95 related articles for article (PubMed ID: 17117455)
1. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
Yao M; Swaminathan A; Srinivas N
Biopharm Drug Dispos; 2007 Jan; 28(1):35-42. PubMed ID: 17117455
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
3. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Tannehill-Gregg SH; Sanderson TP; Minnema D; Voelker R; Ulland B; Cohen SM; Arnold LL; Schilling BE; Waites CR; Dominick MA
Toxicol Sci; 2007 Jul; 98(1):258-70. PubMed ID: 17426106
[TBL] [Abstract][Full Text] [Related]
4. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
5. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
Waites CR; Dominick MA; Sanderson TP; Schilling BE
Toxicol Sci; 2007 Nov; 100(1):248-58. PubMed ID: 17675651
[TBL] [Abstract][Full Text] [Related]
6. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
Dominick MA; White MR; Sanderson TP; Van Vleet T; Cohen SM; Arnold LE; Cano M; Tannehill-Gregg S; Moehlenkamp JD; Waites CR; Schilling BE
Toxicol Pathol; 2006; 34(7):903-20. PubMed ID: 17178691
[TBL] [Abstract][Full Text] [Related]
7. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
[TBL] [Abstract][Full Text] [Related]
8. Subchronic urinary bladder effects of muraglitazar in male rats.
Van Vleet TR; White MR; Sanderson TP; Cohen SM; Cano M; Arnold LL; Waites CR; Schilling BE; Mitroka J; Dominick MA
Toxicol Sci; 2007 Mar; 96(1):58-71. PubMed ID: 17132713
[TBL] [Abstract][Full Text] [Related]
9. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG
Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
Li W; Zhang D; Wang L; Zhang H; Cheng PT; Zhang D; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 May; 34(5):807-20. PubMed ID: 16467134
[TBL] [Abstract][Full Text] [Related]
11. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
Zhang D; Raghavan N; Wang L; Xue Y; Obermeier M; Chen S; Tao S; Zhang H; Cheng PT; Li W; Ramanathan R; Yang Z; Humphreys WG
Drug Metab Dispos; 2011 Jan; 39(1):123-31. PubMed ID: 20876787
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
13. Muraglitazar (Bristol-Myers Squibb/Merck).
Barlocco D
Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
[TBL] [Abstract][Full Text] [Related]
14. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Zhang D; Wang L; Chandrasena G; Ma L; Zhu M; Zhang H; Davis CD; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):139-49. PubMed ID: 17062778
[TBL] [Abstract][Full Text] [Related]
15. Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation.
Xue YJ; Akinsanya JB; Raghavan N; Zhang D
Rapid Commun Mass Spectrom; 2008; 22(2):109-20. PubMed ID: 18059002
[TBL] [Abstract][Full Text] [Related]
16. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Mittra S; Sangle G; Tandon R; Sharma S; Roy S; Khanna V; Gupta A; Sattigeri J; Sharma L; Priyadarsiny P; Khattar SK; Bora RS; Saini KS; Bansal VS
Br J Pharmacol; 2007 Feb; 150(4):480-7. PubMed ID: 17211457
[TBL] [Abstract][Full Text] [Related]
17. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
18. Molecule of the month. Muraglitazar.
Drug News Perspect; 2005 May; 18(4):284. PubMed ID: 16034485
[No Abstract] [Full Text] [Related]
19. Is it safe to combine PPAR agonists? A lesson from muraglitazar.
Stulc T; Ceska R
Med Hypotheses; 2006; 67(3):669. PubMed ID: 16762511
[No Abstract] [Full Text] [Related]
20. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Coletta DK; Fernandez M; Cersosimo E; Gastaldelli A; Musi N; DeFronzo RA
Diabet Med; 2015 May; 32(5):657-64. PubMed ID: 25484175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
